Summary
Eli Lilly and Company reported robust revenue growth of 15% year-over-year for the first quarter of 2022, reaching $7.81 billion. This increase was primarily driven by strong volume growth, particularly from key products like Trulicity, Verzenio, and Jardiance, as well as significant contributions from COVID-19 antibody treatments. Despite the strong top-line performance, the company's net income saw a substantial increase of 40% to $1.9 billion, translating to a diluted EPS of $2.10, up from $1.49 in the prior year period. The company's operational expenses showed a mixed trend. Research and development expenses saw a slight decrease, attributed to lower spending on COVID-19 antibody development, while marketing, selling, and administrative costs remained relatively flat. A notable item was the reduction in acquired in-process R&D expenses. The company also repurchased $1.5 billion in shares during the quarter, signaling a continued commitment to returning capital to shareholders. Eli Lilly maintains a strong financial position with ample liquidity to fund its operations and pipeline development.
Financial Highlights
51 data points| Revenue | $7.81B |
| Cost of Revenue | $2.07B |
| Gross Profit | $5.74B |
| R&D Expenses | $1.61B |
| SG&A Expenses | $1.56B |
| Interest Expense | $84.90M |
| Net Income | $1.90B |
| EPS (Basic) | $2.11 |
| EPS (Diluted) | $2.10 |
| Shares Outstanding (Basic) | 903.70M |
| Shares Outstanding (Diluted) | 906.40M |
Key Highlights
- 1Revenue increased by 15% to $7.81 billion, driven by strong volume growth in key products and COVID-19 antibody treatments.
- 2Net income grew by 40% to $1.9 billion, with diluted Earnings Per Share (EPS) rising to $2.10 from $1.49.
- 3Gross margin improved to 73.5% from 72.4%, supported by favorable product mix and reduced impact from foreign exchange on international inventories.
- 4Research and Development expenses decreased by 4% due to lower COVID-19 antibody development costs, while development for late-stage assets increased.
- 5The company repurchased $1.5 billion of its shares under its authorized share repurchase program.
- 6Key products like Trulicity, Verzenio, and Jardiance demonstrated significant revenue growth.
- 7Revenue from COVID-19 antibodies remained substantial but is expected to be limited starting in the second quarter of 2022.